A recent study supported the benefits of targeting Src-STAT3, which showed that Das and CYT387 (JAK/STAT inhibitor) together synergistically reduced proliferation and induced apoptosis of renal cell carcinoma [50]. Here, SRC is linked to renal cell carcinoma.